Kicking Off Today! Process Intensified. Drug Manufacturing Accelerated. The Sartorius PI Forum opens in Boston -- shaping biomanufacturing's future

• Sartorius launches a premier industry event focused on process intensification (PI) for protein therapeutics and emerging modalities.
• Forum features expert-led sessions, hands-on workshops, and live demonstrations of cutting-edge PI solutions.
• Event underscores the leadership of Sartorius in driving efficient, scalable and sustainable biomanufacturing.

GÖTTINGEN, Germany, June 24, 2025 /PRNewswire/ -- Sartorius, a leading international partner of life science research and the biopharmaceutical industry, is proud to launch the Sartorius PI Forum, taking place June 24–26, 2025, at the Royal Sonesta Boston. This exclusive event brings together biomanufacturing pioneers, innovators, and decision-makers to explore the future of process intensification (PI) for protein therapeutics and emerging modalities.

Complexity Simplified, Progress Accelerated | The Sartorius PI forum spotlights transformative developments in flexible manufacturing, digitalization, automation, and sustainability. These advancements are critical to enabling faster, more efficient, and scalable production across the biopharmaceutical space.

Participants will benefit from a dynamic program featuring:

• Data-driven presentations from industry experts and innovators
• Hands-on workshops focused on practical applications of PI technologies
• Interactive demonstrations of the latest Sartorius solutions

"The pace of change in biomanufacturing is accelerating, and process intensification is at the heart of that transformation," said Maurice Phelan, President of Sartorius North America. "At the Process Intensification Forum, we're not just discussing what's next—we're enabling it. This event is about turning insight into implementation, and bringing together the ecosystem of minds needed to redefine how biologics are made."

"Process intensification is foundational to how we address speed, scale, and sustainability in drug development and manufacturing," said Miriam Monge, Head of Customer & Industry Advocacy Strategy BPS at Sartorius. "Forums like this are essential because they connect strategy with solutions, and help align the science, technology, and partnerships that will define the next generation of therapies."

Whether you're driving innovation in upstream or downstream processes or looking to implement sustainable and digital-first strategies, the Sartorius PI Forum offers actionable insights into the technologies and trends shaping the future of biomanufacturing.

Learn more about how Sartorius is accelerating drug manufacturing through process intensification at.

A profile of Sartorius
Sartorius is a leading international partner to life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions Division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies more safely, rapidly, and sustainably. Based in Göttingen, Germany, the company has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2024, the company generated sales revenue of around 3.4 billion euros. More than 13,500 employees work for customers around the globe.

Visit our Newsroom or follow us on LinkedIn.

Contact
Lars Hanf
Head of BPS Marketing Communications
+491759558820
[email protected]

SOURCE Sartorius